Search - tctmd.com

Displaying 341 - 360 of 622

Sort: Relevancy | Date

News Conference News AHA 2014

AVOIDing Oxygen in Suspected STEMI Tied to Smaller Infarcts, Less Recurrent MI

Yael L. Maxwell

November 18, 2014

News Daily News

一项元分析对在STEMI患者中采取的“一刀切”式的抗凝血剂策略提出了质疑

L.A. McKeown

November 17, 2014

News Daily News

Un Meta Análisis Cuestiona la Estrategia Anticoagulante ‘Talla Única’ en Pacientes STEMI

L.A. McKeown

November 17, 2014

News Conference News AHA 2014

Role of CTA in Survival Prediction, Resource Utilization Explored

November 17, 2014

News Conference News AHA 2014

Registry: Newer P2Y12 Inhibitors Reduce Stent Thrombosis, Mortality Over Clopidogrel

Yael L. Maxwell

November 17, 2014

News Conference News AHA 2014

Novel, Efficient CT-based FFR Outperforms CTA

November 17, 2014

News Conference News AHA 2014

Mitral Repair at the Time of CABG Provides No Mortality, QoL Benefit at 1 Year

Yael L. Maxwell

November 17, 2014

News Daily News

Meta-analysis Questions One-Size-Fits-All Anticoagulant Strategy in STEMI Patients

L.A. McKeown

November 17, 2014

Presentation AHA 2014

Primary Outcomes of the EVOLVE II Trial: A Prospective Randomized Investigation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent

Presenter: Dean J. Kereiakes

November 16, 2014

Presentation AHA 2014

Long-term Outcome of Biodegradable Compared to Durable Polymer Drug-Eluting Stents and Bare Metal Stents – Main Results of a Prospective Randomized Trial

Presenter: C.Kaiser

November 16, 2014

Presentation AHA 2014

Efficacy and safety of vorapaxar in NSTE ACS patients undergoing non-cardiac surgery

Presenter: S. van Diepen

November 16, 2014

News Conference News AHA 2014

Vorapaxar Safe in NSTE-ACS But Bleeding Risk Merits 6-Month Delay Before Noncardiac Surgery

Yael L. Maxwell

November 16, 2014

News Conference News AHA 2014

FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes

November 16, 2014

News Conference News AHA 2014

Ezetimibe Proves Clinical Benefit on Top of Statin Therapy

November 16, 2014

News Conference News AHA 2014

Extending Clopidogrel Past 1 Year Improves Outcomes in DES, But Not BMS Patients

Yael L. Maxwell

November 16, 2014

News Conference News AHA 2014

Long-Term Better than Short-Term Prasugrel After PES Stenting

November 15, 2014

News Conference News AHA 2014

ITALIC Shows Noninferiority of 6-Month DAPT in Good Aspirin Responders

Yael L. Maxwell

November 15, 2014

News Conference News AHA 2014

ISAR-SAFE: Another Randomized Trial Finds 6 Months of DAPT as Good as 12 Months

November 15, 2014

News Industry News

Boehringer Ingelheim Initiates U.S. Sites in First-Ever Global Phase III Trial of Investigational Antidote in Patients Taking PRADAXA®

November 09, 2014

News Industry News

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent Following CE Mark

November 02, 2014

Advertisement

AVOIDing Oxygen in Suspected STEMI Tied to Smaller Infarcts, Less Recurrent MI

一项元分析对在STEMI患者中采取的“一刀切”式的抗凝血剂策略提出了质疑

Un Meta Análisis Cuestiona la Estrategia Anticoagulante ‘Talla Única’ en Pacientes STEMI

Role of CTA in Survival Prediction, Resource Utilization Explored

Registry: Newer P2Y12 Inhibitors Reduce Stent Thrombosis, Mortality Over Clopidogrel

Novel, Efficient CT-based FFR Outperforms CTA

Mitral Repair at the Time of CABG Provides No Mortality, QoL Benefit at 1 Year

Meta-analysis Questions One-Size-Fits-All Anticoagulant Strategy in STEMI Patients

Primary Outcomes of the EVOLVE II Trial: A Prospective Randomized Investigation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent

Long-term Outcome of Biodegradable Compared to Durable Polymer Drug-Eluting Stents and Bare Metal Stents – Main Results of a Prospective Randomized Trial

Efficacy and safety of vorapaxar in NSTE ACS patients undergoing non-cardiac surgery

Vorapaxar Safe in NSTE-ACS But Bleeding Risk Merits 6-Month Delay Before Noncardiac Surgery

FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes

Ezetimibe Proves Clinical Benefit on Top of Statin Therapy

Extending Clopidogrel Past 1 Year Improves Outcomes in DES, But Not BMS Patients

Long-Term Better than Short-Term Prasugrel After PES Stenting

ITALIC Shows Noninferiority of 6-Month DAPT in Good Aspirin Responders

ISAR-SAFE: Another Randomized Trial Finds 6 Months of DAPT as Good as 12 Months

Boehringer Ingelheim Initiates U.S. Sites in First-Ever Global Phase III Trial of Investigational Antidote in Patients Taking PRADAXA®

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent Following CE Mark

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content